Today news
About the same in other media
Sun Pharma subsidiary partners with Aclaris Therapeutics for licensing agreement
Reading now: 329
licensing agreement with Aclaris Therapeutics, Inc., a biopharmaceutical firm focusing on innovative drugs for immuno-inflammatory diseases.
As per the pact, Aclaris grants Sun Pharma exclusive rights to specific patents for using deuruxolitinib, Sun Pharma's JAK inhibitor, or other isotopic forms of ruxolitinib, specifically for treating alopecia areata (AA) or androgenetic alopecia (AGA).
The deal includes a $15 million initial payment, along with subsequent regulatory and commercial milestones, as well as royalties, according to the company's exchange filing.
About this in other media
Stocks in news: Sapphire Foods, PNC Infratech, Nestle, NHPC, Sun Pharma economictimes.indiatimes.com /10 months ago
Sun Pharma, Lupin recall drugs in US over manufacturing issues: USFDA livemint.com /10 months ago
Sun Pharma, Lupin recall drugs in US market: USFDA economictimes.indiatimes.com /10 months ago
Show more
The website fvbb.com is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.
